In December,  for " TAA06 Injection " , one CAR-T cell therapy product targeting  B7-H3, independently developed by PersonGen BioTherapeutics (Suzhou) Co., Ltd.,  the Phase I clinical trial  was officially launched in Tianjin Medical University Cancer Institute & Hospital  for treatment  of  " relapsed/refractory neuroblastoma ". 

In December, Exclusive Interview | Dr. Yang Lin: Cell Drug Entrepreneurship is a " Game " for only a few People.

In December, | PersonGen.Anke Cellular Therapeutics Co., Ltd. won the  " Second Prize " in " The 2nd Anhui Province Life and Health Industry Innovation Competition ".

In December, | PersonGen won  the " Winning Project Award " in  " The 2nd National Disruptive Technology Innovation Competition ".

In November, Xu Tao, academician of the Chinese Academy of Sciences, visited biopharmaceutical key enterprise: PersonGen.Anke Cellular Therapeutics Co., Ltd.

In November, Dr. Yang Lin, Chairman of PersonGen, was listed in the " 2022 China CGT Annual Influential Enterprise Leader ".

In September, ESMO Congress 2022 | PersonGen announced the research results of CAR-T combined with radiotherapy pretreatment for solid tumors.

In September, Dr. Yin Wu, one of the world's top authoritative experts on γδT cell research, became the scientific and medical advisor of PersonGen.

In September, Dr. Yang Lin, founder of PersonGen, accepted an exclusive interview from Hong Kong Commercial Daily.

In September, PersonGen was included in the list of " Top 100 Pharmaceutical Innovative Enterprises of 2022 in China ".

In September, Dr. Yang Lin, founder of PersonGen, won the BioCon Awards for Excellence in Biotechnology and was invited to give a keynote speech.

In September, PersonGen.Anke Cellular Therapeutics Co., Ltd. joined hands with the University of Science and Technology of China and won the special promotion of Anhui Science and Technology News.

In August, Exclusive Interview | The " Unusual " Dr.Yang Lin, Run an Atypical CAR-T Company for 12 Years.

In August, Exclusive Interview | Dr.Yang Lin: IND Approval is No Longer a Bright Spot, Cell Therapy Industry is on the Eve of a Greater Breakthrough in China.

In July, the third   " TONACEA Cell and Gene Therapy Club Council " was held, and Dr. Yang Lin was elected as the executive director.

In July, Interview | PersonGen Yanglin: Current Status and Future of CAR-T Cells Combined with Oncolytic Viruses in the Treatment of Solid Tumors.

In July, the world's first clinical trial of CAR-T therapy (TAA06 injection, targeting B7-H3) for pediatric r/r neuroblastoma was approved by the National Medical Products Administration of China.

In June, PersonGen has built a fully automated CAR-T cell industrialization base in Hefei High-tech Zone.

In May, PersonGen presided over the Development of Major Special Projects of Science and Technology in Anhui Province.

In April, PersonGen announced that the first patient in the Phase I clinical trial of PA3-17 injection had completed the infusion.

In April, PersonGen announced the acceptance of IND Application of B7-H3 CAR-T (TAA06 Injection) by CDE.

In March, TAA06 was granted ODD and RPD for the treatment of neuroblastoma by U.S. FDA.

In January, PersonGen has completed the B Round of Financing led by China Kim Kaide(Xiamen)Innovative Biomedical Equity Investment Fund Partnership(L.P.) and Nanjing Huatai Guoxin Medical Investment Partnership (Limited Partnership) , and co-invested by PANYI(SUZHOU) Capital Management Co.Ltd and Jiangsu Huatong Private Equity Fund Management Co., Ltd.